The University of Texas Health Science Center at San Antonio
uthscsa.eduTotal trials
426
Active
89
Phase 3
13
Total enrollment
53,892
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 61 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pioglitazone | — | — | — | 10 | |||
| Quetiapine | — | — | — | — | — | 2 | |
| Vancomycin | — | — | — | — | — | 1 | |
| Pimavanserin | — | — | — | — | — | 1 | |
| Pioglitazone 45 mg | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | 2 | ||
| Sitagliptin | — | — | — | — | 2 | ||
| Ketamine Hydrochloride | — | — | — | — | — | 1 | |
| Metformin HCI XR | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Pioglitazone 15 MG and 30mg | — | — | — | — | — | 1 | |
| Rapamycin | — | — | — | 7 | |||
| Ropivacaine | — | — | — | — | 2 | ||
| Sacituzumab Govitecan | — | — | — | — | 2 | ||
| Normal saline | — | — | — | — | — | 1 | |
| Memantine | — | — | — | — | — | 1 | |
| Raloxifene | — | — | — | — | — | 1 | |
| IMG-7289 | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| Tremelimumab | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Bupropion Hydrochloride 150 MG | — | — | — | — | — | 1 | |
| Lomustine | — | — | — | — | — | 1 | |
| Imipramine Hydrochloride | — | — | — | — | — | 1 | |
| Empagliflozin 25 MG | — | — | — | 6 | |||
| Metformin | — | — | 7 | ||||
| prednisone | — | — | — | — | 2 | ||
| Roflumilast | — | — | — | — | — | 2 | |
| Avasopasem | — | — | — | — | — | 1 | |
| Loncastuximab | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Lavender Oil | — | — | — | — | — | 1 | |
| Mandarin Oil | — | — | — | — | — | 1 | |
| Peppermint oil | — | — | — | — | — | 1 | |
| Rybelsus | — | — | — | — | — | 1 | |
| Jardiance 25Mg | — | — | — | — | — | 1 | |
| Actos | — | — | — | — | — | 1 |
21 more active programs hidden
Next readouts
- 2023-12-20
- 2024-12-02
- 2026-03
- 2026-04-15
- 2026-04-30
- 2026-05
- 2026-06
- 2026-07
- 2026-07-31
- 2026-08
Top conditions
- Type 2 Diabetes18
- Breast Cancer15
- Aging12
- Schizophrenia12
- Prostate Cancer11
- Bipolar Disorder11
- Diabetes Mellitus, Type 29
- Posttraumatic Stress Disorder8
Frequently asked questions about The University of Texas Health Science Center at San Antonio
- How many clinical trials does The University of Texas Health Science Center at San Antonio have on ClinicalTrials.gov?
- The University of Texas Health Science Center at San Antonio is listed as the lead sponsor on 426 clinical trials in ClinicalTrials.gov, 89 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The University of Texas Health Science Center at San Antonio's trials are in Phase 3?
- 13 of The University of Texas Health Science Center at San Antonio's trials are in Phase 3, spread across 61 active drug programs.
- What therapeutic areas does The University of Texas Health Science Center at San Antonio focus on?
- The University of Texas Health Science Center at San Antonio's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Breast Cancer, Aging, Schizophrenia, Prostate Cancer.
- When are The University of Texas Health Science Center at San Antonio's next clinical trial readouts?
- The University of Texas Health Science Center at San Antonio has 10 upcoming primary-completion readouts tracked here; the soonest is “Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2”, expected around 2023-12-20.